These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 17507469)

  • 1. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization.
    Falkowska E; Kajumo F; Garcia E; Reinus J; Dragic T
    J Virol; 2007 Aug; 81(15):8072-9. PubMed ID: 17507469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of N-linked glycans in the interactions of recombinant HCV envelope glycoproteins with cellular receptors.
    Chen PC; Chuang PK; Chen CH; Chan YT; Chen JR; Lin SW; Ma C; Hsu TL; Wong CH
    ACS Chem Biol; 2014 Jul; 9(7):1437-43. PubMed ID: 24766301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.
    Helle F; Goffard A; Morel V; Duverlie G; McKeating J; Keck ZY; Foung S; Penin F; Dubuisson J; Voisset C
    J Virol; 2007 Aug; 81(15):8101-11. PubMed ID: 17522218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies.
    Lavie M; Hanoulle X; Dubuisson J
    Front Immunol; 2018; 9():910. PubMed ID: 29755477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.
    Harman C; Zhong L; Ma L; Liu P; Deng L; Zhao Z; Yan H; Struble E; Virata-Theimer ML; Zhang P
    J Virol; 2015 Jan; 89(1):492-501. PubMed ID: 25339761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.
    McCaffrey K; Boo I; Owczarek CM; Hardy MP; Perugini MA; Fabri L; Scotney P; Poumbourios P; Drummer HE
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions.
    Helle F; Vieyres G; Elkrief L; Popescu CI; Wychowski C; Descamps V; Castelain S; Roingeard P; Duverlie G; Dubuisson J
    J Virol; 2010 Nov; 84(22):11905-15. PubMed ID: 20844034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.
    Douam F; Dao Thi VL; Maurin G; Fresquet J; Mompelat D; Zeisel MB; Baumert TF; Cosset FL; Lavillette D
    Hepatology; 2014 Mar; 59(3):776-88. PubMed ID: 24038151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.
    Lavie M; Sarrazin S; Montserret R; Descamps V; Baumert TF; Duverlie G; Séron K; Penin F; Dubuisson J
    J Virol; 2014 Sep; 88(18):10584-97. PubMed ID: 24990994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.
    Urbanowicz RA; Wang R; Schiel JE; Keck ZY; Kerzic MC; Lau P; Rangarajan S; Garagusi KJ; Tan L; Guest JD; Ball JK; Pierce BG; Mariuzza RA; Foung SKH; Fuerst TR
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.
    Kalemera MD; Capella-Pujol J; Chumbe A; Underwood A; Bull RA; Schinkel J; Sliepen K; Grove J
    J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33147126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.
    Fenouillet E; Lavillette D; Loureiro S; Krashias G; Maurin G; Cosset FL; Jones IM; Barbouche R
    J Biol Chem; 2008 Sep; 283(39):26340-8. PubMed ID: 18667425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
    Haddad JG; Rouillé Y; Hanoulle X; Descamps V; Hamze M; Dabboussi F; Baumert TF; Duverlie G; Lavie M; Dubuisson J
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region.
    Alhammad Y; Gu J; Boo I; Harrison D; McCaffrey K; Vietheer PT; Edwards S; Quinn C; Coulibaly F; Poumbourios P; Drummer HE
    J Virol; 2015 Dec; 89(24):12245-61. PubMed ID: 26378182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins].
    Goffard A; Lazrek M; Bocket L; Dewilde A; Hober D
    Ann Biol Clin (Paris); 2007; 65(3):237-46. PubMed ID: 17502294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape.
    Zhao Y; Ren Y; Zhang X; Zhao P; Tao W; Zhong J; Li Q; Zhang XL
    J Immunol; 2014 Jul; 193(2):783-96. PubMed ID: 24928988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles.
    Doerrbecker J; Friesland M; Riebesehl N; Ginkel C; Behrendt P; Brown RJ; Ciesek S; Wedemeyer H; Sarrazin C; Kaderali L; Pietschmann T; Steinmann E
    Hepatology; 2014 Aug; 60(2):508-20. PubMed ID: 24771613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry.
    Drummer HE; Boo I; Maerz AL; Poumbourios P
    J Virol; 2006 Aug; 80(16):7844-53. PubMed ID: 16873241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.
    Anjum S; Wahid A; Afzal MS; Albecka A; Alsaleh K; Ahmad T; Baumert TF; Wychowski C; Qadri I; Penin F; Dubuisson J
    J Infect Dis; 2013 Dec; 208(11):1888-97. PubMed ID: 23908491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.
    Bartosch B; Dubuisson J; Cosset FL
    J Exp Med; 2003 Mar; 197(5):633-42. PubMed ID: 12615904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.